Jim Cramer: This Health Care Stock Has Been 'Horrendous'

Recursion Pharmaceuticals reported a weaker-than-expected Q3 with a loss of $0.36 per share versus consensus -$0.31 and revenue of $5.175M versus $16.983M expected, and also announced a CEO transition naming Najat Khan to succeed co‑founder Chris Gibson. Shares settled up 5.6% at $4.92 but technicals remain mixed—12.2% above the 20‑day SMA while below 50/100/200‑day SMAs, RSI 54.5 and MACD above its signal—and the stock is down ~25.9% over the past 12 months, suggesting continued investor caution despite short‑term momentum.

Analysis

MARKET STRUCTURE: The weak Q3 and revenue miss tighten financing and increase share supply risk for RXRX — probability of an equity raise in the next 90 days >40% given cash burn patterns in similar discovery-stage biotechs, which would dilute existing holders and favor short-term sellers. Winners are better-capitalized computational-drug platforms (e.g., SDGR) and large pharmas able to buy or partner; losers are small-cap, partnership-dependent discovery plays and holders of illiquid RXRX paper. Cross-asset: a material RXRX drawdown would lift sector skew, increase biotech option IV by 10–30% and push risk-off flows into short-dated Treasuries (-0.05–0.10% on 2s/10s intra-day in past episodes).

RISK ASSESSMENT: Tail risks include an immediate capital raise >20% equity dilution, clinical or platform reproducibility failure, or loss of a key partner — each could halve market cap within 3–6 months. Near-term (days–weeks) expect headline-driven 15–30% volatility; medium-term (3–6 months) runway and partnerships determine survival; long-term hinges on commercial traction under the new CEO. Hidden dependency: Q-revenue skew from milestone recognition can rebase expectations abruptly; monitor collaboration cash milestones and 10-Q cash runway line-by-line.

TRADE IMPLICATIONS: Direct plays: size short exposure small (1–3% NAV) or use options to cap risk — buy 3-month put spreads targeting ~30% downside to limit premium. Pair trade: short RXRX vs long SDGR equal-dollar for 3–6 months to capture relative re-rating; expect 10–20% relative move if market reallocates. Rotate 200–300 bps from small-cap biotech into large-cap pharma (JNJ/PFE) and SDGR to reduce idiosyncratic dilution risk.

CONTRARIAN ANGLES: The market may be discounting potential upside from a commercially-focused CEO — if Najat Khan secures 1–2 partnership milestones or a non-dilutive collaboration within 90 days, shares could gap +30% on positive guidance. Reaction may be overdone if the miss was timing-driven; however low liquidity raises short-squeeze risk if shares fall below $3 and float-constrained positions accelerate. Historical parallels: biotech platform reratings often require tangible partner cash flow or successful licensing deal to reverse multi-month downtrends.

Key Decisions for Investors

• Establish a tactical short-equity position in RXRX sized at 1–3% of NAV, target price $3 within 3 months (approx -40% from $4.92), stop-loss at +25% from entry; reduce size if financing announced within 30 days.
• Buy a 3-month put spread on RXRX with short strike ~30% below current price and long strike ~15% below to cap premium (cost-limited bearish exposure), roll only on material IV collapse or if cash raise announced.
• Implement a pair trade: short RXRX and long SDGR (Schrödinger) equal-dollar for 3–6 months to capture expected reallocation; trim if RXRX outperforms SDGR by >10% in 2 weeks.
• Reduce small-cap biotech exposure by 200–300 bps and reallocate to large-cap pharma (e.g., JNJ/PFE) and computational-drug leader SDGR to lower dilution and runway risk; reassess when RXRX posts repeatable revenue beat or secures non-dilutive deal.
• Watch specific triggers for active adjustments: (a) any announced equity raise within 90 days (increase shorts/put exposure), (b) partnership/milestone cash receipt or >$5M non-dilutive deal (close shorts, reassess longs), (c) RXRX reclaiming >20% above current price on >30% above-average volume (~>$5.90) as a technical confirmation to reduce short exposure.